EMG
MDGL icon

ETF Managers Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

ETF Managers Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,518
Closed -$469K – 769
2022
Q2 		$469K Buy
+6,518
New +$479K 0.01% 517

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ETF Managers Group's MDGL Position: Q3 2022 in Review

ETF Managers Group sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2022, closing a stake of 6,518 shares — an estimated $469K sold.

ETF Managers Group first reported a position in MDGL in Q2 2022 and held it in 1 quarter. The position peaked at $469K in Q2 2022. 135 funds tracked by Wall St. Rank hold MDGL as of Q3 2022.

  • ETF Managers Group reported no remaining Madrigal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • ETF Managers Group sold 6,518 Madrigal Pharmaceuticals shares in Q3 2022, an estimated $469K.
  • ETF Managers Group first reported a position in Madrigal Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • ETF Managers Group's Madrigal Pharmaceuticals position peaked at $469K in Q2 2022.
  • 135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.